Asia
Meheco Says Diclofenac Sodium Tablets Pass Chinese Drug Regulator's Consistency Evaluation
China Meheco Group's (SHA:600056) unit, Tianfang Pharmaceutical, received approval from China's National Medical Products Administration for its supplemental drug application for diclofenac sodium enteric-coated tablets after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Thursday.The evaluation tested the drug's quality and efficacy.The drug is mainly used for the treatment of inflammatory and degenerative rheumatic diseases, various rheumatic pain and gout.
SHA:600056
